 Zynerba Pharmaceuticals NASDAQ:ZYNE Incs results for the fourth quarter and full year reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel ZYN002. In the financial year ended December 31, 2021, the Devon, Pennsylvania-based company increased its cash and equivalents to 67.8 million compared to 59.2 million at the end of December 2020. 